Article date: February 1995
By: S.J. Hollingsworth, N.P. Shankley, E.M. Anderson, A. Bennett, in Volume 114, Issue 3, pages 715-719
The interaction between methotrexate and indomethacin has been examined, at a physiological folate concentration (20 nm), on a human normal lymphoblast‐like cell line (RPMI 1788) in vitro.
Indomethacin (1 μg ml−1) increased the reduction of lymphoblast growth caused by methotrexate (10–80 ng ml−1).
Indomethacin (0.1 and 1 μg ml−1) potentiated the cytotoxicity of methotrexate (20 and 40 ng ml−1) after 4 days in culture.
Indomethacin (0.4 μg ml−1) reduced the accumulation of tritium in lymphoblasts incubated with [3H]‐methotrexate after 30 min; therefore initial drug accumulation was not responsible for the potentiation seen after 4 days.
If indomethacin increases the killing of human cancer cells by methotrexate in vivo, with a smaller potentiation on lymphoblasts, this combination may be beneficial in treating human malignancy.
The interaction between methotrexate and indomethacin has been examined, at a physiological folate concentration (20 nm), on a human normal lymphoblast‐like cell line (RPMI 1788) in vitro.
Indomethacin (1 μg ml−1) increased the reduction of lymphoblast growth caused by methotrexate (10–80 ng ml−1).
Indomethacin (0.1 and 1 μg ml−1) potentiated the cytotoxicity of methotrexate (20 and 40 ng ml−1) after 4 days in culture.
Indomethacin (0.4 μg ml−1) reduced the accumulation of tritium in lymphoblasts incubated with [3H]‐methotrexate after 30 min; therefore initial drug accumulation was not responsible for the potentiation seen after 4 days.
If indomethacin increases the killing of human cancer cells by methotrexate in vivo, with a smaller potentiation on lymphoblasts, this combination may be beneficial in treating human malignancy.
DOI: 10.1111/j.1476-5381.1995.tb17197.x
View this article